Yahoo Search Búsqueda en la Web

Resultado de búsqueda

  1. Hace 6 días · Sigue la cotización de Cellnex Telecom en directo: acciones, evolución, histórico, dividendos y últimas noticias de Cellnex Telecom y del resto de empresas del mercado en Cinco Días.

    • EUR
    • 30,560
    • 18-04-2024-13:09
    • +0,3942%
  2. Hace 6 días · Berenberg he elevado esta semana su recomendación sobre Cellnex a 'comprar' desde 'mantener' y su precio objetivo hasta 42 euros desde 36 euros. JP Morgan, en un informe de este miércoles ...

  3. Hace 3 días · La firma alemana Berenberg revisa este martes el sector de las telecomunicaciones europeo, con varios cambios de valoración sobre distintas compañías. Así, eleva Cellnex a 'comprar' desde ...

  4. Hace 1 día · Senté Labs New Hydrate Serum. Senté is a medical grade skincare line that specializes in replenishing the skin by diminishing the supply of Heparan Sulfate, a natural component of the skin that needs to regulate inflammation, control visible redness, restore even skin tone, and stay hydrated, plump and firm.

  5. Hace 1 día · Innovative diffusion Magnetic Resonance Imaging (dMRI) models enable in vivo mapping of biologically meaningful properties such as cell size, potential biomarkers in cancer. However, while cancers frequently spread to the liver, models tailored for liver applications and easy to deploy in the clinic are still sought. We tackle this unmet need by delivering a practical and clinically viable ...

  6. Hace 5 días · THERAKOS® CELLEX® Photopheresis SYSTEM Procedural Kits Product Service Code: 6505-Drugs and Biologicals NAICS Code: 325413- In-Vitro Diagnostic Substance Manufacturing Place of Performance: National Institutes of Health Clinical Center 10 Center Drive Bethesda, MD 20892POTS: 24-009065

  7. Hace 6 días · 5 Wall Street analysts have issued 1 year target prices for Celldex Therapeutics' stock. Their CLDX share price targets range from $27.00 to $90.00. On average, they expect the company's stock price to reach $66.00 in the next year. This suggests a possible upside of 86.5% from the stock's current price.